Skip to main content
Clinical Trials/CTRI/2021/06/034489
CTRI/2021/06/034489
Not yet recruiting
Phase 2

A RANDOMIZED CLINICAL STUDY TO EVALUATE THE EFFECTIVENESS OF DHANWANTARA TAILA AS UTTARA BASTI AND ORAL ADMINISTRATION IN THE MANAGEMENT OF VATASHTHEELA WITH SPECIAL REFERENCE TO BENIGN PROSTATE HYPERPLASIA

All India Institute of Ayurveda0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Sponsor
All India Institute of Ayurveda
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subject diagnosed as Benign Prostatic Hyperplasia by clinical and investigative methods will
  • be selected.
  • Patients having IPSS Score 7\- 20 should be included.
  • In USG findings, patients having Prostate gland weight more than 40 gm and Residual Urine
  • Volume above 30 ml should be included.13
  • In uroflometry Qmax 3\- 20 ml/s should be included.

Exclusion Criteria

  • Patients with IPSS (International Prostate Symptom Score) above 20 (severe)
  • Patients having other systemic pathology like Tuberculosis, Renal Failure, Uncontrolled
  • Diabetes Mellitus And Uncontrolled Hypertension Etc..
  • Patients having other urinarysystem pathology like severe Urinary tract
  • infections, Nephrolithiasis, Urethral Stricture, Prostatitis
  • Patients suffering from Prostatic malignancy
  • Patients having congenital deformity of urogenital tract
  • HIV and HBsAg positive patients
  • Patients having PSA value above normal (above 10 ng/ml )should be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials